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Abstract
The HIV Research for Prevention (HIVR4P) conference catalyzes knowledge sharing on biomedical HIV
prevention interventions such as HIV vaccines, antibody infusions, pre-exposure prophylaxis, and microbicides
in totality—from the molecular details and delivery formulations to the behavioral, social, and structural
underpinnings. HIVR4P // Virtual was held over the course of 2 weeks on January 27–28 and February 3–4,
2021 as the COVID-19 pandemic continued to inflict unprecedented harm globally. The HIVR4P community
came together with 1,802 researchers, care providers, policymakers, implementers, and advocates from 92
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countries whose expertise spanned the breadth of the HIV prevention pipeline from preclinical to im-
plementation. The program included 113 oral and 266 poster presentations. This article presents a brief sum-
mary of the conference highlights. Complete abstracts, webcasts, and daily rapporteur summaries may be found
on the conference website (https://www.hivr4p.org/).
Keywords: HIV, HIVR4P, vaccine, antiretrovirals, microbicides, PrEP, South Africa, prevention, clinical trials,
broadly neutralizing antibodies (bNAbs), TaSP
Introduction
The HIV Research for Prevention (HIVR4P) 2020conference was planned, fittingly, to occur in the country
with the highest number of new HIV infections each year,
South Africa.1 In August 2020, amidst a new pandemic, the
International AIDS Society announced that HIVR4P would,
for the first time, be postponed and conducted virtually. By
the time HIVR4P // Virtual conference began at the end of
January 2021, COVID-19 had infected *100 million people
(*1% of all humans) in its first year.2 This is in stark contrast
to the slow burning pandemic of HIV with 76 million people
infected in four decades.3 Because many pioneering inves-
tigators in HIV were simultaneously on the frontlines of the
COVID-19 pandemic, the conference, for the first time, in-
troduced an opportunity to discuss another pandemic.
The quick successes of the COVID-19 response were cer-
tainly aided by the platforms developed for HIV, and will in
turn likely lead to learnings in HIV vaccine development. The
HIV and COVID-19 syndemics will also undoubtedly impact
the trajectory of both diseases over the next decade. The HIV
prevention research community brought HIVR4P // Virtual to
their homes and workplaces across different time zones. Survey
results from conference delegates suggest that HIVR4P //
Virtual may have been especially successful in broadening
access to the conference among African researchers, imple-
menters, and community advocates. In this article, we present
the prominent ideas that emerged. Despite the challenges that
were a feature of 2020, HIV research innovation, interventions,
and implementations did not disappoint.
Vaccines and Antibody Infusions: Trials, Triumphs,
and Tribulations
Decades of HIV vaccine research contributed
to the prompt and adept development
of COVID-19 vaccines
Multidisciplinary HIV vaccine research paved the way for the
COVID-19 vaccine endeavor in at least two important ways. The
first contribution is that existing expertise gained from the HIV
field in structure-based reverse vaccine design4 was galvanized
into designing the stable prefusion spike immunogen used in the
COVID-19 vaccines. Structure-based reverse vaccine design
uses X-ray crystallography, which measures the angles and in-
tensities of X-ray beams diffracted off of crystallized viral en-
velope spike when it is bound to an antibody derived from an
infected person, to determine the structure. Once the binding site
of the antibody is known, a complementary viral antigen is re-
verse engineered to serve as the basis of vaccine candidates.
Structure-based reverse vaccine design succeeded imme-
diately to produce effective COVID-19 vaccines [Presenta-
tion PL01.01; Supplementary Table S1]. However, it has not
yet delivered a highly effective vaccine against HIV, an in-
fection with considerably more complicated challenges.
Unlike COVID-19, antibodies elicited by HIV vaccines have
not yielded protection in most human efficacy trials except
for the partial and waning protection observed in the
modified-intention-to-treat analysis of RV144.5 The second
contribution is that existing infrastructure and expertise at the
HIV trial networks and the global HIV clinical trial sites
allowed for COVID-19 vaccines to be tested with proficiency
in clinical trials [Presentation PL01.01].
Infusions of VRC01 monoclonal broadly neutralizing
antibody did not prevent HIV infection overall
in the Antibody-Mediated Prevention trials, but viral
sensitivity to VRC01 determined its protection efficacy
In natural HIV infection, antibodies that can disable most
HIV strains (broadly neutralizing antibodies, bNAbs) develop
after a couple of years in a minority of individuals.6 The
Antibody-Mediated Prevention (AMP) trials intravenously in-
fused HIV-uninfected volunteers every 2 months with bioen-
gineered copies of VRC01, an antibody that had been isolated
in 2009 from a slow-progressing HIV-infected individual
[Presentation RT03.01]. In preclinical studies, VRC01 dem-
onstrated 70%–90% neutralization breadth measured against a
panel of viruses in the laboratory [Presentation RT03.04].
Retention in AMP was *96% for infusion visits, and
participants stated a good trial experience [Presentation
RT03.02]. AMP has been designed primarily to address the
main question of whether a lower and higher dose of VRC01
monoclonal antibody can prevent HIV infection in diverse
human and viral populations [Presentation RT03.03].
VRC01 proved safe and tolerable, but overall did not have
protection efficacy in both of its Phase 2b proof-of-concept
trials: one among women at risk in Africa (HVTN 703/HPTN
081) and the other among men and transgender persons who
have sex with men in the Americas (HVTN 704/HPTN 085)
[Abstract HY01.01LB].7
In the laboratory, researchers estimated HIV sensitivity to
VRC01 by first infecting TZM-bl cells once in vitro with pseu-
doviruses based on breakthrough HIV strains from the placebo
and VRC01 groups, and then measuring viral neutralization titers.
VRC01 could neutralize about a third of breakthrough viruses,
with most from the placebo group. In a subset analysis estimating
prevention efficacy by considering as endpoints only the break-
through infections that had VRC01 sensitivity (80% inhibitory
concentration, IC80 < 1lg/mL), HIV incidence was lower in the
VRC01 group compared with placebo recipients (estimated
prevention efficacy 75.4%, 95% confidence interval: 45.5–88.9).
In summary, VRC01 could prevent HIV acquisition if
one is exposed to VRC01-sensitive HIV [Presentation
RT03.04]. These findings support researching the admin-
istration of multiple antibodies with a variety of neutrali-
zation profiles to prevent infection with HIV, a virus with
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unparalleled diversity. This is being approached through a
bispecific antibody or combination of antibodies (e.g.,
3BNC117 plus 10-1074) [Presentation RT01.02]. A further
discovery from AMP was that the in vitro serum neutraliza-
tion titer was a predictive marker for in vivo prevention ef-
ficacy, similar to findings from the nonhuman primate (NHP)
studies. The neutralization assays could be used to calibrate
similar studies in future [Presentation RT03.04].
Implications of the AMP studies were deliberated throughout
the conference. The field still needs to discover an efficacious
antibody/regimen. Next-generation antibodies are optimizing
the route and frequency of administration (VRC07-532LS al-
lows for subcutaneous administration and has a longer half-life)
and diversifying binding locations (M4008_N1 binds to the
HIV-1 V3 crown region) [Abstract OA03].7 There was also a
presentation from an in vitro study about another consideration:
how a naturally occurring antibody, IgA, could block the
function of VRC01. Using samples from HIV-uninfected indi-
viduals, high levels of plasma IgA inhibited the function of some
broadly neutralizing antibodies—VRC01, PGT121, VRC03,
and 3BNC117—but not 10-1074 [Abstract OA01].7
Finally, because the VRC01 antibody did not prevent HIV
acquisition overall, there are repercussions on the design of
vaccines being developed to induce broadly neutralizing anti-
bodies. Hypothetically, a vaccine aiming to induce only VRC01-
like antibodies may be as nonefficacious as VRC01 itself.
Not to be discouraged, several strategies to improve the
quality and function of vaccine-elicited VRC01 were presented
at the conference. The first showed a vaccination strategy in the
Vh1-2/LC mouse model to elicit VRC01-like antibodies able to
neutralize the N276 glycan. This included a prime of naked or
glycan-masked eOD-GT8 60-mer followed by gp120 cores with
increasing glycan coverage and a final boost with BG505 trimer
to increase breadth and potency [Abstract OA08.02].7 Another
intriguing strategy to boost B cell proliferation in germinal
centers and activate B cells expressing desired unmutated
VRC01-class heavy and light chains is the use of iv4/iv9 bis-
pecific anti-idiotypic monoclonal Abs [Abstract OA08.05LB].7
Novel HIV vaccine candidates
Although much is still being learned about interactions be-
tween immune system components, and the maturation pathway
from germline antibodies to broadly neutralizing antibodies are
yet to be fully elucidated, current vaccine design is using systems
vaccinology and bioinformatics to aid HIV vaccine design. A key
challenge remains the rapidly evolving viral diversity.
Key vaccine strategies showcased at the conference are
given in Table 1. Major themes in vaccine design were (1)
harnessing messenger RNA to deliver HIV antigens, after the
platform demonstrated successful emergency-use authoriza-
tion for highly effective COVID-19 vaccination; (2) germline
targeting, which is the induction of broadly neutralizing an-
tibodies through vaccination, and (3) selective T cell vaccines
that induce CD8 but not CD4 cells.
Back to Basics: Measure, Design, Test, and Repeat
Engineering next-generation antibodies
for improved function
As made more apparent by the reported failure of VRC01 to
effectively protect overall in the AMP trial,8 next-generation
broadly neutralizing antibodies with increased potency used in
combination are likely to be the most promising way forward
for the success of passive immunization strategies. However, it
is encouraging that beyond this, there are approaches to im-
prove the antibodies themselves. These do not only focus on
neutralization but include Fc-mediated functions. Given the
requirement for several broadly neutralizing antibodies to en-
gage Fc receptors to provide optimal protection from HIV,9,10 it
was heartening to see groups grappling with the detailed Fc
mechanisms and how to translate these into workable vaccine
and passive immunization strategies.
With important implications for the AMP trial, Fc antibody
variants of VRC01 and VRC07-523 with longer half-lives
(M428L/N434S), typically used in clinical trials, showed
differential distribution in the tissues of NHPs. This is despite
these antibodies being clonally related and having the same
Fc modifications. This may be a result of their differential Fc
glycosylation profiles [Abstract OA01.01].7 Similarly, Fc var-
iants, that either enhance or deplete Fc receptor binding of the
same parent antibodies, are also associated with unique cellular
subsets. This suggests that not only will the mutations influence
binding to Fc receptors as intended, but may also alter antibody
localization and, therefore, availability in the mucosa.
Although it is clear that the Fc portion has impact on
protection for broadly neutralizing antibodies through Fc
effector function, it is emerging that it can also influence
neutralization. To illustrate this, antibody subclass was
shown to alter neutralization potency in an antibody lineage
[Abstract OA08.01].7 This suggests that subclass switching
in concert with changes in the Fab portion may act as a
mechanism of neutralization escape.
The association of Fc effector function with the RV144
vaccine efficacy and the formation of FccR immune com-
plexes is required for optimal Fc effector function elicita-
tion.11 Therefore, a computational method to predict levels
required of different subclasses to achieve this was presented.
In this model the biggest enhancement of function in RV144
was seen by increasing Fc receptor affinity for IgG1 anti-
bodies, whereas enhancing binding to antigen had a limited
effect on Fc receptor complex formation [Presentation
SY01.05]. This gives the field insight into how to tune Fc
effector function in a vaccine setting, likely through the
elicitation of favorable Fc glycosylation.
In contrast, a study showing the success of single-chain
variable fragments of broadly neutralizing antibodies used in
combinations that do not have the Fc portion was reported
[Abstract OA08.03].7 Despite having a significantly reduced
neutralization potency compared with the parent bNAbs, in
combination these still showed remarkable potency and
100% breadth. These constructs have the added benefit of
being cost-effective and suitable for adeno-associated virus-
vectored immunoprophylaxis given their small size, suggesting
their promise for targeted passive immunizations in difficult-to-
reach tissues. However, the lack of Fc portion limits their po-
tential targeted use only for prevention of HIV-1 acquisition.
Networking big data to inform vaccine design
The power of large and diverse data sets to examine
multifaceted networks and accurately capture the complexity
of the immune system was on full display. The interaction
between different arms of the immune system is beginning to
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be unraveled with the advent of high-throughput technologies
and the machine-learning techniques to understand the rela-
tionship between data. Certainly, this has been particularly
powerful in understanding responses postvaccination [Pre-
sentations SY08.04 and SY01.03].
In particular, relationships between innate, adaptive,
demographic, and microbiome responses were used to
define responders and nonresponders in two different
HIV vaccine trials [Presentation SY01.01]. Genes, asso-
ciated with bacterial diversity before vaccination, were
correlated with the development of neutralizing antibodies
and were found to be biomarkers of responders in the
second trial. This provides the opportunity to define non-
responders and potentially alter dosage to result in a de-
sired vaccine response.
The ability of vaccines to train innate cells, including
monocytes, dendritic cells, and neutrophils, was also studied
using these integrated methods in a modified vaccinia virus
Ankara vaccine regimen in NHPs [Presentation SY01.03].
Responses were dependent on the vaccine schedule and the
route of administration, and innate immune cells were pheno-
typically more mature/activated suggesting they were more
Table 1. Novel HIV Vaccine Candidates
Vaccine strategy Vaccine Results [conference presentation/abstract]
Messenger RNA HIVConsvM: mRNA lipid nanoparticle
encoding a tetravalent antigen from
conserved regions of HIV
In a preclinical model, polyfunctional T cell
responses were observed [Abstract
OA12.03]7
Viral vectors Vesicular atomatitis virus containing HIV-1
Env chimeras with or without SIV gag in
absence of VSV-G and with or without the
Ebola glycoprotein
Provides protection in macaques against low-
dose cross-clade SHIVenv_SF162_P3
challenge [Abstract OA12.04LB]7
MVAGD5: Modified Vaccinia Ankara
expressing clade C mosaic gag and Du151
envelope
In animals, MVAGD5 elicited neutralizing
antibodies to Tier 1A and Tier 1B viruses but
not to Tier 2 [Abstract OA12.05]7
Cytomegalovirus vector Elicit effective early effector memory T cell
responses: MHC-E restricted CD8 cell
responses under viral genetic control. Phase 1
safety and immunogenicity trial for a spread







ASO1B-adjuvanted eOD-GT8 60mer IAVI G001, a Phase I trial of eOD-GT8 60mer,
demonstrated safety and tolerability, and that
97% of vaccine-recipients produced VRC01-
like antibodies [Presentation SY07.01]
BG505 SOSIP.664, a Clade A gp140 The phase I clinical trial IAVI C101 is testing
adjuvanted BG505 SOSIP.664 gp140
[Presentation SY07.03]
ConM and ConS envelope trimers In EAVI 2020-01, IgG and neutralizing
antibodies were produced [Presentation
SY07.04]
ConMSOSIPv7, a Consensus M envelope
trimer
ACTHIVE001 is enrolling [Presentation
SY07.05]
Combinations Clade C ALVAC plus clade C gp120
adjuvanted with MF59 versus aluminum
hydroxide versus no adjuvant
In HVTN 107, an early-phase trial, co-
administration of ALVAC+gp120+MF59
induced the highest antibody response rates
and magnitudes. Alum-adjuvanted gp120
plus ALVAC downregulated early serum
cytokine responses but MF59 induced
sustained elevated serum cytokine levels
[Abstract OA18.03].7 Alum-adjuvanted
gp120 administered in a prime/boost regimen
with ALVAC reduced early systemic serum
cytokine and chemokine responses to the
vaccine, while MF59 induced a diverse
immunomodulatory cytokine profile
[Abstract OA18.02]7
Prime-boost Adenovirus 26 with synthetic
mosaic antigens plus trimeric gp140
adjuvanted with aluminum phosphate
Efficacy trials HVTN 705 and HVTN 706
ongoing [Presentation SY09.01]
DNA/SeV-CaV11 In rhesus macaques, induced Gag/Vif-specific
CD8 but not CD4 T cells and protection
against repeated intrarectal low-dose
SIVmac239 challenge in 8 of 12 macaques
[Abstract OA09.02]
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equipped to respond to revaccination. The unappreciated role
of natural killer cells in the response to bacille Calmette-Guerin
vaccination in infants and revaccination in adolescents, also
highlighted the cross-talk of the innate and adaptive immune
response and the strength of integrated studies [Presentation
SY03.2].
In addition, the detailed analysis of the antibody response
to immunization of NHPs with NFL trimer required the ex-
amination of large data sets to understand the expansion of
180 clonotypic lineages. Completed by combining single B
cell sequencing of antibody heavy chains with high-
throughput bulk repertoire sequencing and antibody lineage
tracing analysis, this study highlighted that achieving high
levels of somatic hypermutation with repeated boosting leads
to functional antibody improvements, even in minimally
expanded lineages [Presentation SY08.02].
T cells in COVID-19 and HIV
Although the role of T cells in HIV dysregulation is well
described, studies expanded on their role as HIV therapeutic
intervention, function in tissues as well as their somewhat
diminished response in severe COVID-19 infection.
Despite T cells being the major target of HIV infection, a
study made use of novel chimeric antigen receptor T cells
transduced with 4-1BB and CD28 domains and further en-
gineered to protect them from HIV infection that were then
shown to prevent CD4 depletion [Abstract OA20.02].7 In the
hunt for reliable T cell markers, T follicular regulatory cells
are difficult to separate from T follicular helper cells and a
study presented novel biomarkers (DPP4 and FCRL3) of
cells from lymph nodes as well as PBMCs [Presentation
SY06.01]. This opened up the possibility of a more mecha-
nistic study of these cells.
Similarly, although the CD8+ T cell role in HIV infection is
well understood, it was reported that most HIV-specific CD8+
T cells in tissues display tissue-resident memory-like phe-
notypes and those found in the lymph node from elite con-
trollers, in which they are increased, efficiently suppress HIV
[Presentation SY08.03]. Their low presence in the cervix in
precancerous conditions may also suppress the cell-mediated
immune response to HIV [Abstract OA20.04].7
In vaccination, the cellular mucosal responses including
alterations to CD4+ T cells elicited by additional late boosts
to the RV144 ALVAC-HIV/AIDSVAX B/E prime/boost
intramuscular vaccine regimen (RV306) were discussed
[Abstract OA22.02].7 These late boosts induced increases in
alpha-4 beta-7 integrin expression on CD4 T cells indicative
of homing to tissues as well as increases in viral-specific
Th17 cells and IgA plasmablasts. This compartmentalization
of the quantity and quality of the immune response upon
vaccine administration between the periphery and mucosa is
imperative to understand for future vaccine regimens.
In a much-anticipated illustration of how HIV research
infrastructure enabled quick translation to COVID-19, im-
munological memory that included antibodies, B cells, and T
cells was shown to extend to at least 8 months post-SARS-
CoV-2 infection. Type 1 and 3 interferon (IFN) responses
were very much delayed in severe infection leading to a
particularly stunted T cell response. Despite this, 50% and
95% of infected individuals had detectable SARS-CoV-2-
specific CD8+ and CD4+ T cells, respectively, at 8 months
postinfection [Presentation SY08.01]. Of importance, re-
ceptor binding domain antibodies were not predictive of the T
cell response, suggesting that serology tests would not be able
to reflect T cell function. T cells targeted almost 1,000 dif-
ferent epitopes with M, N, and spike proteins only accounted
for 11%–27% of CD4+ responses, further corroborating that
antibody targets are not immunodominant for T cells [Pre-
sentation SY08.05].
Transmission at the mucosa
Clearly, understanding the site and the mechanism of the
initial viral transmission in different population groups is
imperative to the advent of new catered prevention strategies,
and was therefore a major theme of discussion at the
conference.
One such population group is neonates and infants. The
importance of not taking our eyes off of preventing mother-
to-child HIV transmission was highlighted as a remaining
concern of clinical significance. There is a need to utilize
many of the prevention strategies already in place for adults
to further curb the spread of HIV in infants. Broadly neu-
tralizing antibodies passively administered within 24 h after
birth in NHPs successfully eliminated simian-human im-
munodeficiency virus (SHIV) viral reservoirs [Presentation
PL02.01]. There is also progress toward harnessing the dy-
namics of early-life immunity to elicit neutralizing antibodies
by vaccination in infants.
Impressively, immunization of infant NHPs with BG505-
SOSIP trimers showed the development of neutralization.
A similar vaccination strategy in human infants, HVTN135 is
planned using the HIV envelope immunogen, CH505. There
are also significant differences in disease progression be-
tween neonates and infant NHPs, with T cell response being
largely nonexistent in newborns, who failed to mount any
significant antiviral responses, rapidly developing patho-
genesis [Abstract OA20.03]7 indicating the need to continue
to probe the immune system at these different stages of life.
Risk factors for infection and the profile of cells initially
infected were also in the spotlight. After 48 h, Th17 were
some of the earliest cells infected in NHPs following rectal
challenge [Abstract OA22.03].7 Surprising was the predom-
inance of HIV infection in the heart, currently under inves-
tigation. Genital epithelial cells were shown to differentially
transcytose X4 and R5 HIV-1 viruses linked to the regulation
of their respective receptors and type 1 IFN responses [Ab-
stract OA22.01]7 underscoring the potential to manipulate
this for prevention. Risk of infection was associated with the
luteal phase of menstruation in NHPs [Abstract OA22.04]7
and the increased density of HIV target cells in foreskin tissue
after sex likely as a result of coating of the penis with IL-8
rich cervicovaginal secretion [Abstract OA22.05].7
Poor disease progression was noted in men who have sex
with men and individuals with STIs who showed the trans-
mission of the highest number of transmitted/founder viruses
and efficient cell-to-cell spread. Lactic acid, a metabolite
produced by beneficial Lactobacillus species in the female
genital tract, was likely to aid in preventing HIV infection
through its anti-inflammatory and epithelial barrier integrity
enhancing properties in vitro12 [Presentation SY06.04].
In addition to risk factors, the assessment of transmission
pathways in communities is indispensable for guidance on
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where to focus prevention. HIV transmission is primarily
within the bounds of communities known to each other. Men
between the ages of 25 and 35 years transmit HIV four times
more than women within transmission clusters [Presentation
PL03.01]. Likely as a result of higher viral load, most HIV
transmissions are driven by recently infected individuals
with *40% transmission occurring within the first year after
infection.
Understanding viral latency to cure HIV
As the old adage goes, prevention is likely better than cure,
but with*40 million infections worldwide the cure of HIV is
an important goal. Interventions to kill already infected cells
included a combination of neutralizing and non-neutralizing
antibodies that was found to be effective in the clearance of
reactivated cells latently infected with neutralization-
resistant viruses through antibody-dependent cellular cyto-
toxicity (ADCC) [Abstract OA14.01].7 Elimination of
infected cells through this same cytotoxic mechanism could
be achieved by novel Ab-like molecules fused to domains 1
and 2 of soluble CD4, enabling the opening of the trimer. This
allows for potent ADCC-mediating antibodies to target sites
previously inaccessible to them [Abstract OA01.05LB].7
Mechanisms of HIV latency, including the role of CD8+ T
cells and noncytolytic mechanisms that appear to maintain
the latent reservoir in CD4+ T cells, may affect the effec-
tiveness of interventions using latency reversing agents
[Abstract OA14.02].7 In addition, cell-to-cell transmission
may promote HIV latency but may be targeted by
sphingosine-1-phosphate (S1P), which reduces total and in-
tegrated HIV-1 DNA in CD4+ T cells and reduces the pro-
liferative state in these cells [Abstract OA14.04].7
Antiretrovirals: Where Do We Stand?
New technologies to close-in on the moving target
Winnie Byanyima [Presentation PL01.02] reflected that
although there was encouraging progress toward reducing
HIV-related mortality, we have missed the 2020 HIV tar-
gets.13 COVID-19 has highlighted the fragility of the HIV
response, emphasizing the need for increasing efforts to reach
the 2030 targets. Although scientific progress has been phe-
nomenal, Byanyima highlighted inequality as one of the
major challenges in achieving our goals; specifically, the
most vulnerable populations need affordable access for sci-
entific innovations to be made meaningful.
The ambitious new UNAIDS target is for 95% of people at
risk of HIV acquisition using combination prevention by
2025.14 With the targets for favorable societal environments
met, 430,000 HIV-related deaths will be averted and 2.6
million new infections will be prevented. Strengthening the
provision of HIV prevention, and reducing stigma and dis-
crimination will put us on the path to End AIDS by 2030.
Four large Treatment as Prevention (TaSP) studies
found that Universal Test and Treat has had a modest
impact on incidence [Presentation PL04.01]. This may, in
part, be owing to studies not being powered to detect
moderate reductions in HIV risk. In addition, the models
were not age stratified, which is important, because sexual
activity is higher in younger ages and antiretroviral ther-
apy (ART) coverage is higher in older ages. These findings
highlight the importance of targeted efforts to increase
HIV testing and linkage to care, and support retention in
care to promote viral suppression.
Accordingly, there were a number of new technologies with
promising findings. Sinead Delaney-Moretlwe [Presentation
PL02.03] summarized preexposure prophylaxis (PrEP) options
currently in the research pipeline. Important considerations
include the following: what the users want, cost, coverage, and
clinic access as well as what drug and delivery mechanisms are
available.
Trials among cisgender women and pregnant women using
daily oral emtricitabine/tenofovir alafenamide fumarate are
in the pipeline, as well as a phase I trial using a topical TAF
insert combined with elvitegravir. Long-acting cabotegravir
(CAB LA) has been shown to be safe and effective in cis-
gender men, transgender women, and cisgender women in the
HPTN 083 and HPTN 084 trials and gives an adherence
advantage with the 8-weekly injections. After a single in-
tramuscular injection, CAB LA was well tolerated and was
detected in all tissues relevant to HIV acquisition, demon-
strating that long-acting CAB may be an effective single
PrEP agent [Abstract OA04.03].7
In a study investigating the relative efficacy of daily oral
tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) and
CAB LA, CAB LA was superior to TDF/FTC [Abstract
HY01.02LB].7 Women in the CAB LA group had an 89%
lower risk of infection where weekly CAB injections likely
had adherence advantage over daily oral TDF/FTC. CAB is
also being developed for use in implants and microarray
patches (MAP) with positive results from preclinical studies.
Although participants preferred the smallest possible size
MAP for ease of use and being discrete, some participants
said they would accept larger patches with longer duration,
between 1 and 3 months [Abstract OA04.01].7 The benefits of
using the MAP included reduced clinic visits, increased
agency, reduced stigma, and reduced burden on the health
care system. Alexandra Minnis [Abstract OA06.04]7 evalu-
ated the acceptability of multipurpose prevention technolo-
gies by heterosexual couples. In general, women wanted to
involve their partners in their decision. Most preferred oral
tablets that needed to be taken for a longer duration of about a
month. The study underscored the need for a diverse mix of
choices to accommodate couples’ needs.
An 8-week CAB reservoir implant in rhesus macaques
found that the CAB implant demonstrated highly reproduc-
ible findings, an excellent safety profile, and no leakage
[Abstract OA04.04].7 High pharmacokinetic (PK) levels
were detected for up to 16 weeks and no adverse events at
either 4 weeks or 3 months.
Islatravir has high potency to inhibit the reverse transcrip-
tase to suppress HIV-1 and drug-resistant variant replication
and has a 190-hour (1 week) half-life after oral administration,
making it a long-acting oral agent. Sharon Hillier’s [Abstract
OA04.05LB]7 PK results showed that the lowest dose of Is-
latravir that provided full protection to rectally challenged
macaques and full antiviral efficacy in humans living with
HIV. Islatravir trough concentrations for 60 and 120 mg doses
were above the prespecified PK thresholds (0.5 pmol/106
PBMCs), demonstrating that there is leeway for missed doses.
Finally, Ivana Massud [Abstract OA04.02]7 shared find-
ings on the safety and efficacy of long-acting poly-
caprolactone PrEP against vaginal SHIV in six pigtail
6 LAHER ET AL.
macaques versus eight controls. Seven of the controls were
infected after a median of four challenges. All six macaques
in the treatment condition remained uninfected after 6 weeks
and until the 4-month follow-up. An ex vivo pharmacological
profile of tenofovir (TFV) and TAF in human foreskin tissue




Eric Armstrong [Abstract OA19.01]7 reported data from
participants receiving treatment during the phase 2b ran-
domized placebo-controlled trial of LACTIN-V (Lactoba-
cillus crispatus CTV-05). Treatment with LACTIN-V
reduced recurrence of bacterial vaginosis and increased L.
crispatus CTV-05 colonization. LACTIN-V may represent a
novel strategy to reduce HIV risk among women. When in-
serted vaginally, a silk fibroin platform encapsulating HIV
inhibitors, including lectin Griffithsin (Grft), readily dis-
solved and released Grft [Abstract OA19.04LB].7 Tissue
biopsies were fully protected against ex vivo SHIV infection.
Focus groups with men and women indicated a preference for
silk inserts over oral PrEP because it allows for spontaneous
protection in a more attractive, relatable packaging.
Participants reported rectal delivery of dapivirine (DPV)
gel through a vaginal applicator and coital stimulation device
were easy to use [Abstract OA16.03].7 Rectal application of
DPV 0.05% gel was both safe and acceptable to HIV negative
male and female adults and PK results showed detectable
median DPV levels in both plasma and rectal fluid [Abstract
OA16.05].7
PrEP is here: Considerations to achieve continued use
AVAC’s Global PrEP Tracker [Abstract OA11.01]7 indi-
cates that PrEP initiations have increased sixfold from 102,446
in 2016 to 651,586 in 2020. Annual growth, however, has
slowed, with total PrEP initiations globally (928,750) falling
short of UNAIDs’ target of 3 million. This slower than antic-
ipated uptake [Abstract OA11.03]7 and retention [Abstract
OA11.04]7 indicates a need for investment in demand-
generation based on user preferences [Abstract OA11.02]7.
Integrated STI and PrEP services with asymptomatic testing
among PrEP users may be beneficial [Abstract OA16.01].7
Reframing adherence
WHO estimates 50% adherence to long-term medication,
with high health and economic cost of nonadherence [Pre-
sentation SY05.01]. Adherence rates vary between patients
and within the same patients over time and across treatments,
and nonadherence may be a norm, not an exception. Because
subjective measures of adherence are less reliable, there may
be benefits to pharmacological adherence assessment, in-
cluding pharmacy refill data, automatic compilation of dos-
ing history data, electronic monitoring, and ingested sensor
devices [Presentation SY05.04].
Gcobisa Madlolo [Presentation SY05.02] (recipient of
Omolulu Falobi award 2018) presented the perspective of a
PrEP user who revealed that it was not easy to start on PrEP.
She eased into the PrEP journey by finding a PrEP ‘‘buddy’’
for motivation, used phone reminders and adherence cards.
Moreover, improving knowledge, decreasing the cost of ob-
taining PrEP, addressing stigma and encouraging social
support can support adherence [Presentations SY05.02 and
SY05.03].
Achieving the unfulfilled promise of prevention
of mother-to-child transmission
Philippa Musoke [Presentation SY02.01] presented the
progress toward the elimination of mother to child transmission
(MTCT), defined as <20,000 infant infections by 2020 and
elimination by 2030. Although elimination of MTCT is feasible
and some countries are well on their way, this goal requires
>90% of mothers with HIV to be on treatment.
In South Africa, the national lockdown had seen a signif-
icant reduction in clinic headcount under the age of 5 years,
indicating a need for community strategies to encourage
continued antenatal care and ART uptake and adherence
during pregnancy [Presentation SY02.03]. Multilateral en-
gagement with community leaders, state policymakers, and
those who use health care services can offer strategic op-
portunities to address access inequality [Presentation
SY02.03]. Finally, passive antibody prevention in HIV-
exposed infants demonstrates that the approach is acceptable,
no safety concerns are apparent, and is likely to be cost-
effective [Presentation SY02.04].
Addressing the Global HIV Pandemic
Through Social Science, Implementation,
and Advocacy Efforts
Presentations in the areas of implementation, social sci-
ence, and advocacy advanced the discussion of how we sit-
uate our work in the context of successes and challenges in
addressing the global HIV pandemic; how we understand the
barriers and facilitators of getting broad and sustained uptake
of HIV prevention and treatment services; and how we ad-
dress these challenges in light of intersectional identities and
the need for tailored service provision.
The presentations touching on this area acknowledged
the importance of context in determining the success of
prevention at the population level; the heterogeneity of
resources, risks, and access to prevention tools; the corre-
sponding need for a robust set of PrEP formulations and
approaches; the need to include the diverse perspectives and
people in the formulation and testing of prevention ap-
proaches; and the ongoing barriers, including stigma and
COVID-19, to realizing the promise of prevention at the
population level.
Global successes, opportunities, and contexts
Plenary presentations set the stage broadly by celebrating our
collective successes in reducing new HIV infections, increasing
coverage of ART for people living with HIV, and growing
PrEP programs. But many of those same presentations ac-
knowledged that even with declining new infections and in-
creasing treatment, we are still not on the trajectory to meet
global prevention targets.
Winnie Byanyima started the conference [Presentation
PL01.02] with a passionate call for us to celebrate the mile-
stone of the lowest HIV-related annual deaths since 1989
while acknowledging that we are failing in our response. She
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encouraged us to see the global epidemic through an ‘‘in-
equality lens’’: although there are broad successes in reduc-
ing HIV transmissions in some settings, like Eswatini,
Thailand, Vietnam, and among gay men in London, in many
other places the conditions that permit such progress—access
to health care without discrimination and significant funding
for HIV prevention are lacking.
What shapes the differences in contexts that give rise to
varying success in prevention programs, and how can we
promote contexts that favor prevention successes? The an-
swer, Dr. Byanyima suggested, was ‘‘science and rights.’’
Even within the set of prevention tools, there can be differ-
ences in intervention coverage. For example, an analysis of
data from 38 countries [Abstract OA02.03]7 illustrated var-
iation in progress of national programs toward UNAIDS HIV
elimination targets. For annual HIV testing, the coverage was
relatively high in many countries in the South of Africa, but
was lower in central and Western Africa. For condom use
indicators, coverage was uniformly low. Most significantly,
the trend models suggested that no African country evaluated
was on a trajectory to meet UNAIDS 2030 targets for either
HIV testing or condom use.
Heterogeneity of resources, risks and access
A major theme of the presentations related to the hetero-
geneity of resources, risks, and access to prevention tools.
Some prevention tools, like a testing platform [Abstract
OA02.01]7 to distinguish new HIV diagnoses into recent and
nonrecent infections, offer insights that could be used to
target prevention resources toward groups where infections
have occurred in the prior year (in North Carolina, among
younger people), are not in general use. Risks for HIV in-
fection are also still heterogeneous: the high HIV infection
risks of female sex workers [Abstract OA02.04],7 cisgender
men transgender women who have sex with men [Abstract
OA02.05LB],7 and people living in HIV core transmission
areas [Abstract OA02.02]7 are high.
Limitations in access to HIV prevention tools was de-
scribed along two axes: first, the need for more options and
choices for HIV prevention, especially noted as a need for
young women [Presentation PL04.03], and second, with re-
spect to long distance to clinics as a barrier [Abstract
OA07.02].7
Need for robust PrEP tools and programs
for service provision
These diverse needs and limitations to access were re-
flected in calls for a more robust set of choices for PrEP
formulations and approaches. Data from >600 men who have
sex with men (MSM) in the United States described aware-
ness of and interest in event-driven PrEP (ED PrEP): *40%
of survey respondents were aware of ED PrEP, and *1 in 5
expressed a preference for ED PrEP over daily use [Abstract
OA07.03].7 In terms of approaches, Wafaa El-Sadr reviewed
multiple dimensions of choice, including efficacy, safety,
convenience, access, privacy, duration of protection, types of
protection, and costs [Presentation PL04.02]. For young
women in Kenya and South Africa, monthly or bimonthly
injections for PrEP were preferred.
The themes of heterogeneity and prevention choices
highlight the need to include the diverse perspectives and
people in the formulation and testing of prevention ap-
proaches. Presentations throughout the conference used dif-
ferent types of research designs to bring forward the reasons
that people start, discontinue, or avoid PrEP. A presentation
on PrEP ‘‘journeys’’ based on qualitative data to focus on
decision-making, relational aspects of decisions to start PrEP,
and mechanisms for resilience to mitigate mistrust, suspicion
of gossip [Abstract OA07.02].7
Another presentation emphasized that PrEP programs
might assume that all potential PrEP users share a common
goal of reducing the risk of HIV infection, whereas for ado-
lescent girls and young women (AGYW), primary goals may
be more aligned with relationship management [Presentation
SY10.04]. In Thailand, the Tangerine Clinic provides pre-
vention services in the context of a broader range of health
services, including hormone services, for trans people [Pre-
sentation SY10.02]. In this same theme, recognizing multiple
prevention and service needs of people who inject drugs
(PWID) was discussed as a critical need [Presentation
SY10.05].
Ongoing barriers to implementing prevention
Ongoing barriers to promoting PrEP and sustaining PrEP
clients on therapy spoke to a deeper and more stubborn set of
challenges. Stigma was discussed as a barrier to both HIV
prevention efforts and to serving MSM living with HIV; the
influence of stigma spans the globe and was specifically
discussed in the United States and in Ghana [Presentation
SY10.01]. Gossip about PrEP use was described as a threat to
PrEP persistence in the Eastern Cape of South Africa; women
who used PrEP and disclosed to multiple people were less
vulnerable to the ill effects of gossip on the PrEP persistence
[Abstract OA07.04].7
Gender-based violence and intimate partner violence were
identified as factors that might discourage PrEP uptake and
undermine PrEP persistence for AGYW [Abstract
OA07.05LB].7 Access to PrEP was an issue for some, espe-
cially in more rural areas [Abstract PE01.31].7 COVID was
also reported to play a role in lowering PrEP uptake and
persistence through multiple mechanisms, including disrup-
tion of infectious disease clinical programs and inducing
anxiety and other mental health issues that interfered with
starting or maintaining PrEP.
Meaningful involvement of impacted populations
A cross-cutting issue was the involvement of impacted
populations in research and implementation studies. One
presentation highlighted the importance of improving the
inclusion of key populations, including female sex workers,
PWID, men who have sex with men, and trans people, in
prevention research globally. PrEP research with PWID was
noted to be an especially underrepresented area of work
[Presentation SY10.05]. This might mean having the voices
of AGYW in decision-making processes around health pro-
grams, or the provision of sustainable resources for AGYW-
led interventions and local responses.
Across populations with needs for HIV prevention ser-
vices, the concepts of agency and autonomy were cited as
determinants of successful, effective, and sustainable pro-
grams. Leadership by members of impacted populations in
the development of research agendas and programs was
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identified as a critical step to improve the impact of programs
to reduce HIV risk and promote engagement in care for those
living with HIV [Presentation PL04.03].
Concluding Messages
The COVID-19 pandemic upended the world in a matter of
months, rendering an in-person HIVR4P impossible even
after a several-month delay. Serendipitously, the COVID-19
pandemic spurred innovation and dispersed conference
content, enabling more expansive participation than ever
before. Certainly, the level of ongoing HIV research in-
cluding engineering of antibodies for improved protection,
the mining of large data sets for vaccine design, and the
discovery of unexpected roles for cell types in HIV disease
despite the COVID-19 pandemic illustrated the resilience of
HIV researchers. It also highlighted the failure of our col-
lective imaginations: we were not prepared for global econ-
omies, supply chains, and travel to be largely shut down and
essential services for HIV and other communicable and
noncommunicable diseases to be seriously curtailed. How-
ever, the emboldened global response that has been mar-
shaled against COVID-19, and because of COVID-19, has
created opportunities for HIV prevention to benefit.
If tens of billions of dollars can be mobilized to support the
rapid development of multiple vaccines for SARS-CoV-2 in
months, not years, can a similar level of investment be mo-
bilized for accelerated HIV prevention research and devel-
opment? Can the same type of highly parallelized, global
vaccine efficacy trials that worked so well for COVID-19 be
used to more quickly test and iterate on HIV vaccine candi-
dates? Critically, can the global health community do better
in delivering the fruits of this science to have public impact,
and ensure that ART-mediated prevention is available to all
who might benefit, and not follow the same inequitable ac-
cess that the world is now seeing with COVID-19 vaccines?
These questions, and others like them, will undoubtedly be a
poignant topic of discussion in subsequent HIVR4P confer-
ences as the responses to both viruses evolve throughout the
next decade, and perhaps much longer.
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